Global Multiple Sclerosis Drugs Market 2014-2018
出 版 商：Infiniti Research
出版日期：2014/08/20
頁 數：102頁
文件格式：PDF
價 格：
USD 3,000 (Single-User License)
USD 3,300 (Multi-User License)
USD 4,000 (Global-User License)
USD 3,300 (Multi-User License)
USD 4,000 (Global-User License)
About Multiple Sclerosis and Disease Types
Multiple sclerosis is a chronic, inflammatory medical condition that results in demyelination, axonal transection, and neurodegeneration. The myelin sheath is damaged because of an abnormal response by the immune system, which targets neurons within the central nervous system (CNS). It is a potentially debilitating disease in which the damage of the myelin sheath causes disruption in the communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed in a patient with multiple sclerosis are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual with the severe course of the disease can experience speech problems and movement problems. Multiple sclerosis can be broadly classified into four types: relapsing-remitting multiple sclerosis, secondary-progressive multiple sclerosis, primary-progressive multiple sclerosis, and progressive-relapsing multiple sclerosis. On the basis of the route of drug administration, the Global Multiple Sclerosis Drugs market can be segmented into two: Oral Drugs, and Parenteral Drugs.
TechNavio's analysts forecast the Global Multiple Sclerosis Drugs market to grow at a CAGR of 5.56 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis.
TechNavio's report, the Global Multiple Sclerosis Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Multiple Sclerosis Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
‧ Americas
‧ APAC
‧ EMEA
Key Vendors
‧ Bayer
‧ Biogen Idec
‧ Merck Serono
‧ Novartis
‧ Teva Pharmaceutical
Other Prominent Vendors
‧ AB Science
‧ Abbvie
‧ Acorda
‧ Active Biotech
‧ GlaxoSmithKline
‧ Glenmark
‧ Mitsubishi Tanabe
‧ Opexa
‧ Pfizer
‧ Sanofi
Market Driver
‧ Unmet Medical Needs
‧ For a full, detailed list, view our report
Market Challenge
‧ Unknown Etiology of the Disease
‧ For a full, detailed list, view our report
Market Trend
‧ Introduction of Disease-modifying Drugs
‧ For a full, detailed list, view our report
Key Questions Answered in this Report
‧ What will the market size be in 2018 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
Multiple sclerosis is a chronic, inflammatory medical condition that results in demyelination, axonal transection, and neurodegeneration. The myelin sheath is damaged because of an abnormal response by the immune system, which targets neurons within the central nervous system (CNS). It is a potentially debilitating disease in which the damage of the myelin sheath causes disruption in the communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed in a patient with multiple sclerosis are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual with the severe course of the disease can experience speech problems and movement problems. Multiple sclerosis can be broadly classified into four types: relapsing-remitting multiple sclerosis, secondary-progressive multiple sclerosis, primary-progressive multiple sclerosis, and progressive-relapsing multiple sclerosis. On the basis of the route of drug administration, the Global Multiple Sclerosis Drugs market can be segmented into two: Oral Drugs, and Parenteral Drugs.
TechNavio's analysts forecast the Global Multiple Sclerosis Drugs market to grow at a CAGR of 5.56 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis.
TechNavio's report, the Global Multiple Sclerosis Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Multiple Sclerosis Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
‧ Americas
‧ APAC
‧ EMEA
Key Vendors
‧ Bayer
‧ Biogen Idec
‧ Merck Serono
‧ Novartis
‧ Teva Pharmaceutical
Other Prominent Vendors
‧ AB Science
‧ Abbvie
‧ Acorda
‧ Active Biotech
‧ GlaxoSmithKline
‧ Glenmark
‧ Mitsubishi Tanabe
‧ Opexa
‧ Pfizer
‧ Sanofi
Market Driver
‧ Unmet Medical Needs
‧ For a full, detailed list, view our report
Market Challenge
‧ Unknown Etiology of the Disease
‧ For a full, detailed list, view our report
Market Trend
‧ Introduction of Disease-modifying Drugs
‧ For a full, detailed list, view our report
Key Questions Answered in this Report
‧ What will the market size be in 2018 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Betaferon/Betaseron/Extavia
04.1.2 Avonex/Rebif
04.1.3 Fampyra
04.1.4 Tecfidera
04.1.5 Tysabri
04.1.6 Gilenya
04.1.7 Copaxone
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Rate of Incidence and Prevalence
08. Market Segmentation by Molecule Type
08.1 Global Biologics Market
08.1.1 Market Size and Forecast
08.2 Global Small Molecules Market
08.2.1 Market Size and Forecast
09. Market Segmentation by Route of Administration
09.1 Global Oral Drugs Market
09.1.1 Market Size and Forecast
09.2 Global Parenteral Drugs Market
09.2.1 Market Size and Forecast
10. Geographical Segmentation
10.1 Multiple Sclerosis Market in the US
10.1.1 Market Size and Forecast
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.2.1 Bayer
18.2.2 Biogen Idec
18.2.3 Merck Serono
18.2.4 Novartis
18.2.5 Teva Pharmaceuticals
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Bayer
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Segmentation
19.1.4 Business Strategy
19.1.5 Sales Segmentation by Business
19.1.6 Sales by Geographical Segmentation
19.1.7 Key Information
19.1.8 SWOT Analysis
19.2 Biogen Idec
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation by Revenue 2013
19.2.4 Geographical Segmentation by Revenue 2013
19.2.5 Business Strategy
19.2.6 Key Developments
19.2.7 SWOT Analysis
19.3 Merck Serono
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Geographical Segmentation by Revenue 2013
19.3.4 Business Strategy
19.3.5 Recent Developments
19.3.6 SWOT Analysis
19.4 Novartis
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation by Revenue 2013
19.4.4 Business Segmentation by Revenue 2012 and 2013
19.4.5 Sales by Geography
19.4.6 Business Strategy
19.4.7 Key Developments
19.4.8 SWOT Analysis
19.5 Teva Pharmaceuticals
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation
19.5.4 Business Segmentation by Revenue 2013
19.5.5 Business Segmentation by Revenue 2012 and 2013
19.5.6 Sales by Geography
19.5.7 Business Strategy
19.5.8 Key Developments
19.5.9 SWOT Analysis
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Multiple Sclerosis Drugs Market 2013-2018 (US$ billion)
Exhibit 3: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type
Exhibit 4: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type 2013
Exhibit 5: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type 2018
Exhibit 6: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type 2013-2018 (US$ billion)
Exhibit 7: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type 2013-2018 (in percent)
Exhibit 8: Global Biologics Market 2013-2018 (US$ billion)
Exhibit 9: Global Small Molecules Market 2013-2018 (US$ billion)
Exhibit 10: Global Multiple Sclerosis Drugs Market by Route of Administration
Exhibit 11: Global Multiple Sclerosis Drugs Market by Route of Administration 2013
Exhibit 12: Global Multiple Sclerosis Drugs Market by Route of Administration 2018
Exhibit 13: Global Multiple Sclerosis Drugs Market Segmentation by Route of Administration 2013-2018 (US$ billion)
Exhibit 14: Global Multiple Sclerosis Drugs Market Segmentation by Route of Administration 2013-2018 (in percent)
Exhibit 15: Global Oral Drugs Market 2013-2018 (US$ billion)
Exhibit 16: Global Parenteral Drugs Market 2013-2018 (US$ billion)
Exhibit 17: Global Multiple Sclerosis Drugs Market by Geography 2013
Exhibit 18: Multiple Sclerosis Market in the US 2013-2018 (US$ billion)
Exhibit 19: Global Multiple Sclerosis Drugs Market by Vendor Segmentation 2013
Exhibit 20: Global Sales Comparison of Betaseron/Betaferon 2010-2013 (US$ million)
Exhibit 21: Sales of Avonex 2011-2013 (US$ million)
Exhibit 22: Sales of Tysabri 2011-2013 (US$ million)
Exhibit 23: Sales of Fampyra 2011-2013 (US$ million)
Exhibit 24: Sales Comparison of Avonex, Tysabri and Fampyra 2011-2013 (US$ million)
Exhibit 25: Sales of Rebif 2010-2013 (US$ million)
Exhibit 26: Sales of Rebif in North America 2010-2013 (US$ million)
Exhibit 27: Sales of Rebif in Europe 2010-2013 (US$ million)
Exhibit 28: Sales of Rebif in Emerging Markets and RoW 2010-2013 (US$ million)
Exhibit 29: Geography-wise Sales of Rebif 2010-2013 (US$ million)
Exhibit 30: Sales of Gilenya 2010-2013 (US$ million)
Exhibit 31: Sales of Extavia 2010-2013 (US$ million)
Exhibit 32: Sales of Gilenya and Extavia 2010-2013 (US$ million)
Exhibit 33: Quarter-wise Sales of Copaxone 2011-2013 (US$ million)
Exhibit 34: Quarter-wise Sales of Copaxone in the US 2011-2013 (US$ million)
Exhibit 35: Quarter-wise Sales of Copaxone Outside the US 2011-2013 (US$ million)
Exhibit 36: Business Segmentation of Bayer AG 2013
Exhibit 37: Sales Comparison of Bayer AG by Business Segment 2012 and 2013 (US$ million)
Exhibit 38: Sales Segmentation of Bayer AG by Geography 2013
Exhibit 39: Biogen Idec: Business Segmentation by Revenue 2013
Exhibit 40: Biogen Idec: Geographical Segmentation by Revenue 2013
Exhibit 41: Merck Serono: Geographical Segmentation by Revenue 2013
Exhibit 42: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 43: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 44: Novartis AG: Sales by Geography 2013
Exhibit 45: Teva Pharmaceutical Industries Ltd.: Business Segmentation
Exhibit 46: Teva Pharmaceutical Industries Ltd.: Business Segmentation by Revenue 2013
Exhibit 47: Teva Pharmaceutical Industries Ltd.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 48: Teva Pharmaceutical Industries Ltd.: Sales by Geography 2013
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Betaferon/Betaseron/Extavia
04.1.2 Avonex/Rebif
04.1.3 Fampyra
04.1.4 Tecfidera
04.1.5 Tysabri
04.1.6 Gilenya
04.1.7 Copaxone
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Rate of Incidence and Prevalence
08. Market Segmentation by Molecule Type
08.1 Global Biologics Market
08.1.1 Market Size and Forecast
08.2 Global Small Molecules Market
08.2.1 Market Size and Forecast
09. Market Segmentation by Route of Administration
09.1 Global Oral Drugs Market
09.1.1 Market Size and Forecast
09.2 Global Parenteral Drugs Market
09.2.1 Market Size and Forecast
10. Geographical Segmentation
10.1 Multiple Sclerosis Market in the US
10.1.1 Market Size and Forecast
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.2.1 Bayer
18.2.2 Biogen Idec
18.2.3 Merck Serono
18.2.4 Novartis
18.2.5 Teva Pharmaceuticals
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Bayer
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Segmentation
19.1.4 Business Strategy
19.1.5 Sales Segmentation by Business
19.1.6 Sales by Geographical Segmentation
19.1.7 Key Information
19.1.8 SWOT Analysis
19.2 Biogen Idec
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation by Revenue 2013
19.2.4 Geographical Segmentation by Revenue 2013
19.2.5 Business Strategy
19.2.6 Key Developments
19.2.7 SWOT Analysis
19.3 Merck Serono
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Geographical Segmentation by Revenue 2013
19.3.4 Business Strategy
19.3.5 Recent Developments
19.3.6 SWOT Analysis
19.4 Novartis
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation by Revenue 2013
19.4.4 Business Segmentation by Revenue 2012 and 2013
19.4.5 Sales by Geography
19.4.6 Business Strategy
19.4.7 Key Developments
19.4.8 SWOT Analysis
19.5 Teva Pharmaceuticals
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation
19.5.4 Business Segmentation by Revenue 2013
19.5.5 Business Segmentation by Revenue 2012 and 2013
19.5.6 Sales by Geography
19.5.7 Business Strategy
19.5.8 Key Developments
19.5.9 SWOT Analysis
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Multiple Sclerosis Drugs Market 2013-2018 (US$ billion)
Exhibit 3: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type
Exhibit 4: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type 2013
Exhibit 5: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type 2018
Exhibit 6: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type 2013-2018 (US$ billion)
Exhibit 7: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type 2013-2018 (in percent)
Exhibit 8: Global Biologics Market 2013-2018 (US$ billion)
Exhibit 9: Global Small Molecules Market 2013-2018 (US$ billion)
Exhibit 10: Global Multiple Sclerosis Drugs Market by Route of Administration
Exhibit 11: Global Multiple Sclerosis Drugs Market by Route of Administration 2013
Exhibit 12: Global Multiple Sclerosis Drugs Market by Route of Administration 2018
Exhibit 13: Global Multiple Sclerosis Drugs Market Segmentation by Route of Administration 2013-2018 (US$ billion)
Exhibit 14: Global Multiple Sclerosis Drugs Market Segmentation by Route of Administration 2013-2018 (in percent)
Exhibit 15: Global Oral Drugs Market 2013-2018 (US$ billion)
Exhibit 16: Global Parenteral Drugs Market 2013-2018 (US$ billion)
Exhibit 17: Global Multiple Sclerosis Drugs Market by Geography 2013
Exhibit 18: Multiple Sclerosis Market in the US 2013-2018 (US$ billion)
Exhibit 19: Global Multiple Sclerosis Drugs Market by Vendor Segmentation 2013
Exhibit 20: Global Sales Comparison of Betaseron/Betaferon 2010-2013 (US$ million)
Exhibit 21: Sales of Avonex 2011-2013 (US$ million)
Exhibit 22: Sales of Tysabri 2011-2013 (US$ million)
Exhibit 23: Sales of Fampyra 2011-2013 (US$ million)
Exhibit 24: Sales Comparison of Avonex, Tysabri and Fampyra 2011-2013 (US$ million)
Exhibit 25: Sales of Rebif 2010-2013 (US$ million)
Exhibit 26: Sales of Rebif in North America 2010-2013 (US$ million)
Exhibit 27: Sales of Rebif in Europe 2010-2013 (US$ million)
Exhibit 28: Sales of Rebif in Emerging Markets and RoW 2010-2013 (US$ million)
Exhibit 29: Geography-wise Sales of Rebif 2010-2013 (US$ million)
Exhibit 30: Sales of Gilenya 2010-2013 (US$ million)
Exhibit 31: Sales of Extavia 2010-2013 (US$ million)
Exhibit 32: Sales of Gilenya and Extavia 2010-2013 (US$ million)
Exhibit 33: Quarter-wise Sales of Copaxone 2011-2013 (US$ million)
Exhibit 34: Quarter-wise Sales of Copaxone in the US 2011-2013 (US$ million)
Exhibit 35: Quarter-wise Sales of Copaxone Outside the US 2011-2013 (US$ million)
Exhibit 36: Business Segmentation of Bayer AG 2013
Exhibit 37: Sales Comparison of Bayer AG by Business Segment 2012 and 2013 (US$ million)
Exhibit 38: Sales Segmentation of Bayer AG by Geography 2013
Exhibit 39: Biogen Idec: Business Segmentation by Revenue 2013
Exhibit 40: Biogen Idec: Geographical Segmentation by Revenue 2013
Exhibit 41: Merck Serono: Geographical Segmentation by Revenue 2013
Exhibit 42: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 43: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 44: Novartis AG: Sales by Geography 2013
Exhibit 45: Teva Pharmaceutical Industries Ltd.: Business Segmentation
Exhibit 46: Teva Pharmaceutical Industries Ltd.: Business Segmentation by Revenue 2013
Exhibit 47: Teva Pharmaceutical Industries Ltd.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 48: Teva Pharmaceutical Industries Ltd.: Sales by Geography 2013
